| | Number of studies | SMD (95% CI) | | | |
| IL-8 & DR | | | | | | Total | 3 | 0.38 (-0.05, 0.81) | 0.078 | 60.80% | 0.087 | IL-8 & DME | 5 | 1.68 (0.97, 2.40) | <0.001 | 81.00% | <0.001 | Subgroup | | | | | | Countries | | | | | | Asian | 4 | 1.86 (0.95, 2.77) | <0.001 | 83.90% | <0.001 | European | 1 | 1.08 (0.45, 1.71) | 0.001 | N.A | N.A | DR diagnosis criteria | | | | | | ETDRS | 3 | 2.05 (0.61, 3.49) | 0.005 | 88.90% | <0.001 | Diabetic Retinopathy Disease Severity Scale | 1 | 1.49 (1.04, 1.93) | <0.001 | N.A | N.A | Cytokine measurements | | | | | | Luminex xMAP suspension array | 3 | 1.84 (0.42, 3.25) | 0.011 | 90.50% | <0.001 | BD Cytometric Bead Array | 1 | 1.61 (0.68, 2.54) | 0.001 | N.A | N.A | Multiplex bead immunoassay | 1 | 1.49 (1.04, 1.93) | <0.001 | N.A | N.A | Remove each study for sensitivity analysis | | | | | | Lee et al., 2012 | 4 | 1.87 (1.0, 2.74) | <0.001 | 83.90% | <0.001 | Jonas et al., 2012 | 4 | 1.86 (0.95, 2.77) | <0.001 | 83.90% | <0.001 | Umazume et al., 2013 | 4 | 1.71 (0.85, 2.58) | <0.001 | 85.70% | <0.001 | Chen et al., 2017 | 4 | 1.77 (0.72, 2.82) | 0.001 | 85.70% | <0.001 | Noma et al., 2017 | 4 | 1.32 (1.01, 1.62) | <0.001 | 0% | 0.525 | IL-12 & DR | | | | | | Total | 3 | 0.44 (-081, 1.70) | 0.488 | 94.20% | <0.001 | IP-10 & DR | | | | | | Total | 2 | 0.31 (-0.16, 0.77) | 0.017 | 20.50% | 0.262 | TNF-α & DR | | | | | | Total | 4 | 0.51 (-0.04, 1.06) | 0.067 | 80.20% | 0.002 |
|
|